Basaglar injection for long-acting insulin treatment in diabetes

Basaglar is a long-acting insulin glargine injection used to help control blood sugar levels in adults and children with type 1 diabetes and in adults with type 2 diabetes. It acts over an extended period to maintain steady insulin levels.

Basaglar is prescribed to improve glycemic control in the following patient groups:

• Adults and pediatric patients with type 1 diabetes mellitus, as part of a regimen including short-acting insulin.
• Adults with type 2 diabetes mellitus requiring basal insulin therapy.

Limitations: Basaglar is not recommended for treating diabetic ketoacidosis.

Insulin glargine

Basaglar contains insulin glargine, a long-acting human insulin analog. After subcutaneous injection, it provides a slow and steady release of insulin, helping to regulate blood glucose levels consistently over 24 hours.

Administration and Dosing Guidelines

• Administer subcutaneously once daily at any time of day but consistently at the same time each day.
• Inject into the abdominal area, thigh, or deltoid, rotating injection sites within the same region to reduce risks of lipodystrophy or localized cutaneous amyloidosis.
• Do not dilute or mix Basaglar with other insulins or solutions.
• Do not administer intravenously or via an insulin pump.
• Visually inspect the pen for clarity; use only if the solution is clear and colorless without particles.
• Each Basaglar pen dials in 1 unit increments with a maximum of 80 units per injection.

Starting Dosage

• Type 1 diabetes: Start with approximately one-third of total daily insulin requirements using Basaglar; remaining insulin needs are met with short- or rapid-acting insulin.
• Type 2 diabetes: Start with 0.2 units/kg or up to 10 units once daily.

Changing Insulin Regimens

• When switching from another insulin glargine 100 units/mL product, use the same dose of Basaglar.
• When switching from insulin glargine 300 units/mL to Basaglar, begin at 80% of the previous dose.
• When switching from twice-daily NPH insulin to once-daily Basaglar, use 80% of the total daily NPH dose initially.
• Adjust doses based on metabolic needs, blood glucose monitoring, and clinical response under medical supervision.

• During episodes of hypoglycemia.
• Known hypersensitivity to insulin glargine or any of the excipients in Basaglar.

Important Warnings and Precautions

• Never share Basaglar pens: Sharing pens poses risks of transmitting blood-borne pathogens.
• Hypoglycemia: The most common adverse effect; can be life-threatening. Patients should monitor glucose frequently, especially during dose changes, changes in meal patterns, physical activity, or with concomitant medications that alter glucose control.
• Medication errors: Accidental mix-ups between insulin products have occurred. Always verify the insulin label before injection.
• Hypersensitivity reactions: Severe allergic reactions including anaphylaxis may occur; discontinue immediately if symptoms arise and provide appropriate medical treatment.
• Hypokalemia: Insulin shifts potassium intracellularly, potentially causing severe hypokalemia, which can lead to respiratory paralysis or cardiac arrhythmias. Monitor potassium in at-risk patients.
• Fluid retention and heart failure: When used with thiazolidinediones (TZDs), fluid retention may worsen or cause heart failure. Monitor for symptoms and consider adjusting therapy.
• Injection site reactions: Avoid injecting into areas of lipodystrophy or localized cutaneous amyloidosis; these areas may affect insulin absorption and glucose control.

Common and Serious Side Effects

Common adverse reactions (≥5%) excluding hypoglycemia include injection site reactions, allergic reactions, lipodystrophy, pruritus, rash, edema, and weight gain.

Infections observed during clinical trials included nasopharyngitis and upper respiratory tract infections.

Hypoglycemia is the most frequent and potentially serious adverse reaction; severe hypoglycemia can cause seizures and may be fatal.

Other adverse reactions reported in clinical trials may include hypertension, sinusitis, cataracts, bronchitis, back pain, cough, urinary tract infection, diarrhea, depression, and headache.

Caution is advised when Basaglar is used with medications that affect blood sugar or potassium levels. Beta-blockers may reduce hypoglycemia awareness. Thiazolidinediones may increase risk of fluid retention and heart failure.

Overdose can cause severe hypoglycemia which may be life-threatening. Treatment involves immediate intake of carbohydrates, monitoring, and supportive care as needed.

Store Basaglar pens according to labeled instructions, typically refrigerated before first use. Do not freeze. Protect from light and do not use if solution is cloudy or contains particles.